Tomomi Okubo

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima et al. · ESMO Open · 2022 · 124 citations · Full text

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 123 citations · Full text

Oncology, Hepatology, Medicine +8

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice

Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada et al. · Hepatology Research · 2022 · 77 citations · Full text

Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka et al. · Hepatology International · 2022 · 77 citations

C-reactive Protein, Hepatology, Hepatocellular Carcinoma Patients +10

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada et al. · Cancer Reports · 2021 · 76 citations · Full text